FDA CDER 2026 Guidance Agenda: Key Focus Areas for Industry

The Center for Drug Evaluation and Research under the U.S. Food and Drug Administration has published a list of guidance documents it may develop in 2026. This includes new Level 1 draft guidances and revisions to previously issued ones.

The agency notes that the list reflects current priorities but is not mandatory. CDER may choose not to issue all listed documents and can also introduce additional guidances on emerging topics.

Among the planned pharmaceutical quality-related guidances are updates on PET drug CGMP requirements, responses to Form FDA 483 observations, and considerations for AI and machine learning in manufacturing. Other focus areas include container closure systems, postapproval changes to drug substances, site master files, and stability recommendations.

Overall, the agenda signals continued regulatory emphasis on quality systems, innovation, and lifecycle management within pharmaceutical manufacturing.

15-03-2026